A parallelized, perfused 3D triculture model of leukemia for in vitro drug testing of chemotherapeutics
Source abstract
Abstract
Abstract Leukemia patients undergo chemotherapy to combat the leukemic cells (LCs) in the bone marrow. During therapy not only the LCs, but also the blood-producing hematopoietic stem and progenitor cells (HSPCs) may be destroyed. Chemotherapeutics targeting only the LCs are urgently needed to overcome this problem and minimize life-threatening side-effects. Predictive in vitro drug testing systems allowing simultaneous comparison of various experimental settings would enhance the efficiency of drug development. Here, we present a three-dimensional (3D) human leukemic bone marrow model perfused using a magnetic, parallelized culture system to ensure media exchange. Chemotherapeutic treatment of the acute myeloid leukemia cell line KG-1a in 3D magnetic hydrogels seeded with mesenchymal stem/stromal cells (MSCs) revealed a greater resistance of KG-1a compared to 2D culture. In 3D tricultures with HSPCs, MSCs and KG-1a, imitating leukemic bone marrow, HSPC proliferation decreased while KG-1a cells remained unaffected post treatment. Non-invasive metabolic profiling enabled continuous monitoring of the system. Our results highlight the importance of using biomimetic 3D platforms with proper media exchange and co-cultures for creating in vivo-like conditions to enable in vitro drug testing. This system is a step towards drug testing in biomimetic, parallelized in vitro approaches, facilitating the discovery of new anti-leukemic drugs.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Hematopoietic Stem Cell Transplantation · Acute Myeloid Leukemia Research · Virus-based gene therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (68)
Show source-provided references
1. Hematopoietic stem cells: the paradigmatic tissue-specific stem cell10.2353/ajpath.2006.060312 ↗
2. Hematopoiesis10.1101/cshperspect.a008250 ↗
3. Hematopoietic stem cell: self-renewal versus differentiation10.1002/wsbm.86 ↗
4. Acute myeloid leukemia10.1056/NEJMra1406184 ↗
5. What you need to know about leukemia
6. A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression10.3109/07357909809115775 ↗
7. Childress · 2015 · p 2210.1007/978-3-319-21702-4_1 ↗
8. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche10.1038/nature09262 ↗
9. Reconstitution of the functional human hematopoietic microenvironment derived from human mesenchymal stem cells in the murine bone marrow compartment10.1182/blood-2005-06-2211 ↗
10. Normal and leukemic stem cell niches: insights and therapeutic opportunities10.1016/j.stem.2015.02.014 ↗
11. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers10.1038/leu.2008.299 ↗
12. Regulation of hematopoietic and leukemic stem cells by the immune system10.1038/cdd.2014.89 ↗
13. The third dimension bridges the gap between cell culture and live tissue10.1038/nrm2236 ↗
14. A practical guide to hydrogels for cell culture10.1038/nmeth.3839 ↗
15. 3D cell culture systems: advantages and applications10.1002/jcp.24683 ↗
16. Biomimetic macroporous PEG hydrogels as 3D scaffolds for the multiplication of human hematopoietic stem and progenitor cells10.1016/j.biomaterials.2013.10.038 ↗
17. Magnetic macroporous hydrogels as a novel approach for perfused stem cell culture in 3D scaffolds via contactless motion control10.1002/adhm.201701403 ↗
18. 3D models of the hematopoietic stem cell niche under steady-state and active conditions10.1038/s41598-017-04808-0 ↗
19. A three-dimensional ex vivo tri-culture model mimics cell-cell interactions between acute myeloid leukemia and the vascular niche10.3324/haematol.2016.157883 ↗
20. Versatile humanized niche model enables study of normal and malignant human hematopoiesis10.1172/JCI89364 ↗
21. Mimicking the acute myeloid leukemia niche for molecular study and drug screening10.1089/ten.tec.2016.0404 ↗
22. Three dimensional spheroid cell culture for nanoparticle safety testing10.1016/j.jbiotec.2015.01.001 ↗
23. Deconstructing the third dimension: how 3D culture microenvironments alter cellular cues10.1242/jcs.079509 ↗
24. Culturing patient-derived malignant hematopoietic stem cells in engineered and fully humanized 3D niches10.1073/pnas.2114227118 ↗
25. Ex vivo expansion of hematopoietic stem cells derived from umbilical cord blood in rotating wall vessel10.1016/j.jbiotec.2006.01.020 ↗
26. Stirred culture of peripheral and cord blood hematopoietic cells offers advantages over traditional static systems for clinically relevant applications10.1002/(sici)1097-0290(19980905)59:5<534::aid-bit2>3.0.co;2-b ↗
27. The hollow fiber bioreactor as a stroma-supported, serum-free ex vivo expansion platform for human umbilical cord blood cells10.1002/biot.201300320 ↗
28. Metabolic profiling of hematopoietic stem and progenitor cells during proliferation and differentiation into red blood cells10.1016/j.nbt.2015.05.002 ↗
29. Introduction to the molecular basis of cancer metabolism and the Warburg effect10.1007/s11033-015-3857-y ↗
30. Targeting the adenosinergic axis in chronic lymphocytic Leukemia: a way to disrupt the tumor niche?10.3390/ijms19041167 ↗
31. Ectonucleotidases in blood malignancies: a tale of surface markers and therapeutic targets10.3389/fimmu.2019.02301 ↗
32. Caspase mediated enhanced apoptotic action of cyclophosphamide- and resveratrol-treated MCF-7 cells10.1254/jphs.08173FP ↗
33. Inhibitory effect of imatinib on normal progenitor cells in vitro10.1182/blood-2003-05-1535 ↗
34. Rödling · 2014 · p 12110.1007/7651_2014_84 ↗
35. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug10.1038/nrd839 ↗
36. Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling10.1038/srep27378 ↗
37. Mechanistic Models for Myelosuppression10.1023/A:1023573429626 ↗
38. Clinical pharmacokinetics of cyclophosphamide10.2165/00003088-200544110-00003 ↗
39. The leukemic stem cell niche: current concepts and therapeutic opportunities10.1182/blood-2009-01-202606 ↗
40. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells10.1016/j.bbrc.2010.03.138 ↗
41. Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia10.1038/sj.leu.2404358 ↗
42. Retinoic acid induction of CD38 antigen expression on normal and leukemic human myeloid cells: relationship with cell differentiation10.1080/1042819031000060564 ↗
43. Induced differentiation of acute myeloid leukemia cells by activation of retinoid X and liver X receptors10.1038/leu.2013.202 ↗
44. Effects of phorbol ester on translocation and down-regulation of protein kinase C and phosphorylation of endogenous proteins in human acute myeloid leukemia cell line KG-1 and its phorbol ester-resistant subline KG-1a
45. The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations10.1038/leu.2011.238 ↗
46. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling10.1038/nm.4210 ↗
47. Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model10.1038/leu.2011.210 ↗
48. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin10.1038/sj.leu.2403899 ↗
49. Epigenetic perturbations by Arg882-mutated DNMT3A potentiate aberrant stem cell gene-expression program and acute leukemia development10.1016/j.ccell.2016.05.008 ↗
50. DNMT3A mutation-induced CDK1 overexpression promotes leukemogenesis by modulating the interaction between EZH2 and DNMT3A10.3390/biom11060781 ↗
51. FLT3 mutations in acute myeloid leukemia cell lines10.1038/sj.leu.2402740 ↗
52. Modulation of FLT3 through decitabine-activated C/EBPa-PU.1 signal pathway in FLT3-ITD positive cells10.1016/j.cellsig.2019.109409 ↗
53. NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia10.1038/leu.2014.231 ↗
54. Myeloid toxicity of cancer treatment10.6004/jadpro.2012.3.4.2 ↗
55. In vitro biomimetic engineering of a human hematopoietic niche with functional properties10.1073/pnas.1805440115 ↗
56. Development and molecular characterization of polymeric micro-nanofibrous scaffold of a defined 3D niche for in vitro chemosensitivity analysis against acute myeloid leukemia cells10.2147/IJN.S80397 ↗
57. A novel three-dimensional stromal-based model for in vitro chemotherapy sensitivity testing of leukemia cells10.3109/10428194.2013.793323 ↗
58. 3D culture enhances chemoresistance of ALL Jurkat cell line by increasing DDR1 expression10.3892/etm.2019.7153 ↗
59. Three dimensional de novo micro bone marrow and its versatile application in drug screening and regenerative medicine10.1177/1535370215594583 ↗
60. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia10.1371/journal.pone.0107587 ↗
61. In vitro modeling of tissue-specific 3D microenvironments and possible application to pediatric cancer research10.14205/2309-3021.2014.02.01.5 ↗
62. Syntheses and biological evaluation of 1,2,3-triazole and 1,3,4-oxadiazole derivatives of imatinib10.1016/j.bmcl.2016.01.068 ↗
63. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-110.18632/oncotarget.11063 ↗
64. Moving myeloid leukemia drug discovery into the third dimension10.3389/fped.2019.00314 ↗
65. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells10.1126/scitranslmed.3000349 ↗
66. Bone-marrow haematopoietic-stem-cell niches10.1038/nri1779 ↗
67. Extracellular adenosine sensing—a metabolic cell death priming mechanism downstream of p5310.1016/j.molcel.2013.03.016 ↗
68. Human mesenchymal stromal cells inhibit platelet activation and aggregation involving CD73-converted adenosine10.1186/s13287-018-0936-8 ↗